Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company') today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference taking place June 3-5, 2025, in New York, NY. The Company will also participate in one-on-one meetings.
Jefferies Global Healthcare Conference - June 3-5, 2025
Format: Company Presentation
Day/Time: Wednesday, June 4 at 1:25 P.M. ET
Webcast: https://wsw.com/webcast/jeff319/ptgx/1883080
If you are interested in meeting with the Protagonist team during the conference, please reach out to your Jefferies representative.
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]
Media Contact
Virginia Amann, Founder/CEO
+1 833 500 0061 ext 1
ENTENTE Network of Companies
[email protected]
SOURCE: Protagonist Therapeutics
press release

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

21 minutes ago

• Yahoo

Save Your Batteries, This Solar-Powered Security Camera Is 50% off Right Now

Are you looking to outfit your home with a new smart security camera? While sales events like Prime Day in July are a great time to buy, you can get this excellent Eufy wireless solar-powered 2K security camera today for only $65. The Eufy Solocam S220 is a capable outdoor security camera like any other, only it has a few fancy tricks up its sleeve. You won't have to run a bunch of long power wires or deal with constantly replacing or recharging batteries, something most security cameras struggle with. That's because this outdoor security camera is solar-powered and only needs about three hours of sunlight to keep tabs on your home daily. Eufy's Solocam S220's MSRP is $130, although it is often discounted to under $100. Lucky for you, Amazon just slashed the price by 50%, making this stellar camera only $64.99. So, what does this camera offer, and what can you expect for your money? Well, quite a bit, thankfully. It's easy to mount just about anywhere, although you'll want a spot with plenty of sunshine. Then, pair it with the Eufy app, and you'll get crystal-clear 2K resolution video of all the happenings around your home. While the battery inside is charged by the solar cell, you shouldn't have to deal with it at all. The Eufy Solocam S220 offers night vision thanks to an Infrared LED and movement detection. It also uses AI to detect familiar faces, animals, and more to know when a notification is worth sending. That way, you won't get alerts for a branch blowing in the wind. This outdoor solar-powered security camera only takes about five minutes to install. It has a durable IP67 rating to handle any outdoor conditions, 2-way audio, and custom security zones you can customize in the app, to name a few. More importantly, there's no monthly fee with Eufy, so you buy once and enjoy peace of mind for years to come. If there's a downside, the unit only has 8GB of storage, so storage space is somewhat limited. Either way, this solid camera makes home security a breeze. Grab yours before it sells out.

Yahoo

22 minutes ago

• Yahoo

Lightroom is working on a solution to my most-hated part of photo editing – and I couldn't be more excited

When you buy through links on our articles, Future and its syndication partners may earn a commission. Between taking photos and editing photos sits one of my least favorite parts of photography: culling, or the process of choosing which photos to edit. As a wedding photographer, culling a gallery of several thousand images takes hours of clicking through to find the best shots. But Adobe Lightroom is working on a new tool that could help speed up the culling process. In a teaser on social media, Adobe shared that developers are working on AI filters, a tool that works to recognize throw-away shots, like shots that are out of focus and blinking portraits. The AI filters, like many of the Lightroom tools, use a slider, allowing photographers to control how strictly to apply these auto-selection filters. A clean-up slider will also help remove accidental shutter triggers, as well as shots that are over- or underexposed. The AI will also be able to auto-group similar shots together, like those taken with burst mode. AI culling tools aren't new – but the tools that exist are third-party platforms and plug-ins that add to the growing number of subscriptions. While I hate culling, my growing subscription aversion has prevented me from buying AI culling software. The idea of getting faster culling without another subscription is one that I can get on board with (albeit one that has recently increased in price). I'm a Lightroom Classic user, and many of the latest AI-based tools have saved me a lot of time. If AI can do to culling what subject selection did to masking, then such a tool would save me hours of sifting through photographs. Sometimes, accidental photos end up as happy surprises – an out-of-focus shot that still captures the emotion of the moment, for example. That's why I'm excited by AI-supportive culling that adds speed yet still leaves the photographer in the driver's seat. But where I think AI culling can save the most time is picking the best shot out of several similar images. I spent a lot of time looking at similar photos to find the one that's the sharpest and discarding the close-eye shots. When I chatted with Adobe during the B&H Bild Expo in New York, Adobe indicated the AI filtering would be coming later this year to both Lightroom Classic and Lightroom Desktop. AI-based subject detection has saved me hours on tasks like whitening teeth, without even using generative AI. I have high hopes that the upcoming Lightroom AI Filters tool brings more of the same time-saving shortcuts to culling. Tired of culling too? Browse the best photo culling software. Or, take a look at the best photo editing software.

Yahoo

36 minutes ago

• Yahoo

Tesla vs. Waymo: What is the difference between the vehicles?

Tesla's robotaxis are set to hit the streets of Austin, Texas. When it comes to self-driving vehicles, the EV giant faces stiff competition from the Alphabet-backed Waymo (GOOG, GOOGL), which already has vehicles on the roads in several cities, one of which may soon be New York City. Stifel NextGen Transport analyst Stephen Gengaro has ridden in both vehicles. He shares his key takeaways from his experiences and why, ultimately, Tesla (TSLA) may have a leg up on the rival. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.